SHANGHAI and HONG KONG, Dec. 17, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental New Drug […]